C5 and malignant hypertension: Alongside a reiteration of the importance of complement C5 inhibitor therapy in patients with aHUS, the results of this study provide evidence that, in patients presenting with MHT and comorbid TMA, complement genetic screening and consideration of a differential diagnosis of aHUS are warranted to allow for prompt and correct treatment decisions.